April 16, 2026 · Form 4 insider transaction
Del Giudice Matthew Paul bought 50,000 shares of Telomir Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 102 days after the transaction.
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.; The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.